What is Quincy Bioscience?
Headquartered in Madison, Wisconsin, Quincy Bioscience is a specialized biotechnology firm dedicated to the discovery and commercialization of novel technologies aimed at supporting cognitive function. The company is best known for its patented use of apoaequorin, a calcium-binding protein originally identified in jellyfish, which serves as the core ingredient in its flagship product, Prevagen. By maintaining a cGMP-compliant manufacturing facility and adhering to rigorous safety standards, the company has successfully positioned itself as a leader in the cognitive health supplement category. Their business model relies on a synthesis of Nobel Prize-winning scientific foundations and robust clinical validation, which has allowed them to achieve significant market penetration and recognition as one of the fastest-growing private companies in the United States.
How much funding has Quincy Bioscience raised?
Quincy Bioscience has raised a total of $5.2M across 1 funding round:
Unspecified
$5.2M
Unspecified (2009): $5.2M, investors not publicly disclosed
Key Investors in Quincy Bioscience
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support the commercialization of biotechnology innovations.
Undisclosed Investor
A private equity participant focused on high-growth life sciences and consumer health ventures.
Undisclosed Investor
A strategic backer specializing in the development of proprietary health technologies and market-ready wellness solutions.
What's next for Quincy Bioscience?
Looking ahead, Quincy Bioscience is poised to leverage its recent capital injection to further validate its product efficacy through expanded clinical trials and research initiatives. The strategic focus will likely remain on deepening the scientific narrative surrounding apoaequorin while simultaneously scaling distribution channels to maintain its status as a top-selling brain support brand. As the company matures, the integration of additional health-focused technologies and potential expansion into broader wellness categories will be critical for sustaining long-term growth. Investors and industry analysts will be monitoring the firm's ability to maintain its competitive edge in the face of increasing regulatory scrutiny and the evolving landscape of the dietary supplement industry.
See full Quincy Bioscience company page
